Xenon Pharmaceuticals (XENE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.79B and a free-cash-flow yield of -9.0%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -4.9% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-46.1%
How far the last close sits under the highest price of the past five years.
Market cap
$3.79B
Trailing P/E
—
Price / book
3.0
Price / sales
—
FCF yield
-9.0%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
-7.4%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
XENE earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$1.14).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$1.11
-$1.16
+4.3%
$0
Q1 2026
May 7, 2026
-$1.17
-$1.20
+2.5%
$0
Q4 2025
Feb 26, 2026
-$1.31
-$1.21
-8.3%
$0
Q3 2025
Nov 3, 2025
-$1.15
-$1.16
+0.9%
$0
XENE analyst price target
Median target $72.00 from 16 analysts, ranging $46.00 – $90.00.
Nama's AI scorecard currently rates Xenon Pharmaceuticals Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does XENE report earnings?
Xenon Pharmaceuticals's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.14.
What is the XENE price target?
The median analyst price target from 16 analysts is $72.00, with a range of $46.00 – $90.00.
Is XENE Shariah compliant?
Nama's AAOIFI-style screen reads Xenon Pharmaceuticals as Can't Tell. A figure the screen needs is missing, so it can't tell.